A Comprehensive Overview Of Active Electroporation Cancer Trials [View article]
In response to Inovio defenders:
1) I made a mistake of even including Inovio here, as there is no current active record on clinicaltrials.gov of an electroporation cancer trial at all. The cervical cancer trial is in fact for intraepithelial neoplasia, which is PRE-cancerous and COULD LEAD to cancer, and one of the exclusionary criteria is actually having cancer. Meaning, patients with cervical cancer are not even qualified to participate in this trial. See here:
2) For all the different angles one can see Inovio's past failure with head and neck cancer, and there are many, the bottom line is, it failed. Perhaps it will succeed next time. Better management, successes that "show promise" or "potential", are beside the point. Its most important trial, most expensive trial, a phase III, did not work. For investors, this is what matters most. Those that see the silver lining are welcome to go long.
3) Yes, OncoSec is licensing technology from Inovio. It seems that OncoSec is making better use of it considering its own results so far with melanoma. We'll see if this continues to pan out, or not.
Here's What Happened The Last Time The Fed Owned All Outstanding Treasuries [View article]
Geoffster -
The US wasn't exactly on the gold standard during WWII. It was on an international gold exchange standard with foreign central banks and would only redeem gold to them. Owning gold in the US was illegal. The US was on the Bretton Woods system by then, which was similar to the Gold Exchange standard of the 1920's centered on London. Gold was still a slight check to inflation back then. Now, it isn't, which changes the whole game.
Turnaround In Northwest Biotherapeutics: Improved Financials And Nasdaq Listing [View article]
Homer -
Regarding the 10 year trial, a large and important part of the results is post operative survival time. In a sense, the longer the better, because that means the patients are surviving, thank God, and that the GBM treatment was successful. Data is still being collected, but this won't stop them from completing the next phase. The FDA certainly is not going to require all patients to pass away before approval, which would be crazy.
Inside Trading Points To Promising New Development In NovaBay [View article]
Hi Wiesemc -
I understand your point of view, but I think you're overlooking a few things. First of all, regarding viral conjunctivitis, true it won't kill you and doesn't last long, but saying that an effective treatment for it won't sell is like saying a treatment for the common cold won't sell either. 7-14 days is a lot of time. Plus, many cases of viral pink eye can get serious and cause long term vision damage.
As for impetigo, according to the CDC, 6,639 deaths were caused by MRSA in 2005 alone. So there is need for a better treatment, or these people would not have died.
In the USA there are segments that pay enormous amounts of after tax money for both private and parochial education for their children. The fact that some of these institutions take advantage of various governmental programs i.e., books, transportation and meals, does not mean they are subsidized. Those institutions thrive and could survive with out those subsidies.
I disagree with your assessment when it relates to Chinese Education. In China and much of Asia, education is the ticket to a higher status. In China, their one child policy allows middle and upper middle class families to invest in their child. Additionally, western educational programs are perceived as a higher quality education when compared to the public school system. That is why families are lining up to get their children accepted into these programs.
Many of these educational programs are for the most part cash up front businesses and considering China has the largest middle class in history the volume is what is generating the growth in revenues.
Just take a look at the private health care sector in China and you will also see a similar growth pattern. Why? Because the best doctors are available and care is better managed.
As for not trusting the numbers, you may have a point. Considering past auditing fiascos involving another major firm, I doubt very much that Deloitte would risk their stellar reputation for a few dollars.
A Comprehensive Overview Of Active Electroporation Cancer Trials [View article]
1) I made a mistake of even including Inovio here, as there is no current active record on clinicaltrials.gov of an electroporation cancer trial at all. The cervical cancer trial is in fact for intraepithelial neoplasia, which is PRE-cancerous and COULD LEAD to cancer, and one of the exclusionary criteria is actually having cancer. Meaning, patients with cervical cancer are not even qualified to participate in this trial. See here:
http://1.usa.gov/10GNSll
2) For all the different angles one can see Inovio's past failure with head and neck cancer, and there are many, the bottom line is, it failed. Perhaps it will succeed next time. Better management, successes that "show promise" or "potential", are beside the point. Its most important trial, most expensive trial, a phase III, did not work. For investors, this is what matters most. Those that see the silver lining are welcome to go long.
3) Yes, OncoSec is licensing technology from Inovio. It seems that OncoSec is making better use of it considering its own results so far with melanoma. We'll see if this continues to pan out, or not.
Here's What Happened The Last Time The Fed Owned All Outstanding Treasuries [View article]
The US wasn't exactly on the gold standard during WWII. It was on an international gold exchange standard with foreign central banks and would only redeem gold to them. Owning gold in the US was illegal. The US was on the Bretton Woods system by then, which was similar to the Gold Exchange standard of the 1920's centered on London. Gold was still a slight check to inflation back then. Now, it isn't, which changes the whole game.
Turnaround In Northwest Biotherapeutics: Improved Financials And Nasdaq Listing [View article]
http://bit.ly/Zhstzz
This PIII was filed in 2006, but enrollment is now in full swing. Primary completion in 4 months, top line results in 2014. Those are the key points.
Turnaround In Northwest Biotherapeutics: Improved Financials And Nasdaq Listing [View article]
Regarding the 10 year trial, a large and important part of the results is post operative survival time. In a sense, the longer the better, because that means the patients are surviving, thank God, and that the GBM treatment was successful. Data is still being collected, but this won't stop them from completing the next phase. The FDA certainly is not going to require all patients to pass away before approval, which would be crazy.
Ophthalmology Market: Healthy Growth, But Only A Few Companies Possess Robust Drug Pipelines [View article]
Inside Trading Points To Promising New Development In NovaBay [View article]
I understand your point of view, but I think you're overlooking a few things. First of all, regarding viral conjunctivitis, true it won't kill you and doesn't last long, but saying that an effective treatment for it won't sell is like saying a treatment for the common cold won't sell either. 7-14 days is a lot of time. Plus, many cases of viral pink eye can get serious and cause long term vision damage.
As for impetigo, according to the CDC, 6,639 deaths were caused by MRSA in 2005 alone. So there is need for a better treatment, or these people would not have died.
http://1.usa.gov/YGg8D4
NVC-422 is applicable to many pathogens, not just viral pink eye and MRSA. That's where the potential is.
What The Intermittent Windshield Wiper Can Teach Pfizer About InSite Vision [View article]
Education In China Is A Sure Bet [View article]
I disagree with your assessment when it relates to Chinese Education. In China and much of Asia, education is the ticket to a higher status. In China, their one child policy allows middle and upper middle class families to invest in their child. Additionally, western educational programs are perceived as a higher quality education when compared to the public school system. That is why families are lining up to get their children accepted into these programs.
Many of these educational programs are for the most part cash up front businesses and considering China has the largest middle class in history the volume is what is generating the growth in revenues.
Just take a look at the private health care sector in China and you will also see a similar growth pattern. Why? Because the best doctors are available and care is better managed.
As for not trusting the numbers, you may have a point. Considering past auditing fiascos involving another major firm, I doubt very much that Deloitte would risk their stellar reputation for a few dollars.